References
- Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417–429
- Melgar, S., and F. Shanahan. 2010. Inflammatory bowel disease-from mechanisms to treatment strategies. Autoimmunity 43: 463–477
- Mizoguchi, A., and E. Mizoguchi. 2008. Inflammatory bowel disease, past, present and future: lessons from animal models. J. Gastroenterol. 43: 1–17
- Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521–533
- Ince, M. N., and D. E. Elliott. 2007. Immunologic and molecular mechanisms in inflammatory bowel disease. Surg. Clin. North Am. 87: 681–696
- Sakaguchi, S. 2008. Regulatory T cells in the past and for the future. Eur. J. Immunol. 38: 901–937
- Lourenco, E. V., and A. La Cava. 2011. Natural regulatory T cells in autoimmunity. Autoimmunity 44: 33–42
- Buckner, J. H. 2010. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10: 849–859
- Bossowski, A., M. Moniuszko, M. Dabrowska, et al. 2013. Lower proportions of CD4 + CD25(high) and CD4 + FoxP3, but not CD4 + CD25 + CD127(low) FoxP3 + T cell levels in children with autoimmune thyroid diseases. Autoimmunity 46: 222–230
- Zheng, Y., and A. Y. Rudensky. 2007. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8: 457–462
- Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science (New York, N.Y.). 299: 1057–1061
- Liu, W., A. L. Putnam, Z. Xu-Yu, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J. Exp. Med. 203: 1701–1711
- Bennett, C. L., J. Christie, F. Ramsdell, et al. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20–21
- Gibson, D. J., E. J. Ryan, and G. A. Doherty. 2013. Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease. Inflamm. Bowel Dis. 19: 2716–2724
- Kamikozuru, K., K. Fukunaga, S. Hirota, et al. 2009. The expression profile of functional regulatory T cells, CD4 + CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. Clin. Exp. Immunol. 156: 320–327
- Takahashi, M., K. Nakamura, K. Honda, et al. 2006. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Digest. Dis. Sci. 51: 677–686
- Maul, J., C. Loddenkemper, P. Mundt, et al. 2005. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128: 1868–1878
- Eastaff-Leung, N., N. Mabarrack, A. Barbour, et al. 2010. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J. Clin. Immunol. 30: 80–89
- Wang, Y., X. P. Liu, Z. B. Zhao, et al. 2011. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J. Dig. Dis. 12: 286–294
- Guidi, L., C. Felice, A. Procoli, et al. 2013. FOXP3+ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents. Biomed. Res. Int. 2013: 286368. doi: http://dx.doi.org/10.1155/2013/286368
- Yokoyama, Y., K. Fukunaga, Y. Fukuda, et al. 2007. Demonstration of low-regulatory CD25High + CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig. Dis. Sci. 52: 2725–2731
- Lichtiger, S., D. H. Present, A. Kornbluth, et al. 1994. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330: 1841–1845
- Tseng, K.-C., Y.-C. Ho, Y.-H. Hsieh, et al. 2012. Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J. Gastroenterol. 47: 823–833
- Boschetti, G., S. Nancey, F. Sardi, et al. 2011. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm. Bowel Dis. 17: 160–170
- Holmén, N., A. Lundgren, S. Lundin, et al. 2006. Functional CD4 + CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm. Bowel Dis. 12: 447–456
- Yu, Q. T., M. Saruta, A. Avanesyan, et al. 2007. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm. Bowel Dis. 13: 191–199
- Moes, N., F. Rieux-Laucat, B. Begue, et al. 2010. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology 139: 770–778
- Chauhan, S. K., D. R. Saban, H. K. Lee, and R. Dana. 2009. Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J. Immunol. 182: 148–153